342 COMPARISON OF THE INCIDENCE OF SECONDARY CANCERS AFTER IMRT, BRACHYTHERAPY AND SURGERY FOR THE TREATMENT OF PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology and Natural History II1 Apr 2012342 COMPARISON OF THE INCIDENCE OF SECONDARY CANCERS AFTER IMRT, BRACHYTHERAPY AND SURGERY FOR THE TREATMENT OF PROSTATE CANCER Tatiana Teslova, Xin Pei, Deborah Kuk, James Eastham, Juan Martin Magsanoc, Marisa Kollmeier, Brett Cox, Zhigang Zhang, and Michael J. Zelefsky Tatiana TeslovaTatiana Teslova New York, NY More articles by this author , Xin PeiXin Pei New York, NY More articles by this author , Deborah KukDeborah Kuk New York, NY More articles by this author , James EasthamJames Eastham New York, NY More articles by this author , Juan Martin MagsanocJuan Martin Magsanoc New York, NY More articles by this author , Marisa KollmeierMarisa Kollmeier New York, NY More articles by this author , Brett CoxBrett Cox New York, NY More articles by this author , Zhigang ZhangZhigang Zhang New York, NY More articles by this author , and Michael J. ZelefskyMichael J. Zelefsky New York, NY More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.403AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To report on the incidence of second malignancy (SM) development after external-beam radiotherapy (EBRT) and brachytherapy (BRT) for prostate cancer and compare to a contemporaneously cohort treated with radical prostatectomy (RP). METHODS Between 1998 and 2001, 2733 patients with localized prostate cancer were treated with EBRT (n=897) or BRT (n=413) and RP (n=1423). Using the RP cohort as a control we compared the incidence of SM such as rectal or bladder cancers noted in the field of radiotherapy (IF) and out of the field cancers (OOF) for these patients. Competing risk analyses were used to calculate SM-free survival outcomes. RESULTS The 10-year SM-free survival (including skin cancers) for the RP, BRT and EBRT cohorts were 87%, 85% and 75%, respectively (RP vs. EBRT P<0.001, and RP vs. BRT P=0.37). The 10-year likelihoods for in-field (IF) SM development in these groups were 4%, 2%, and 4%,respectively (p=0.38). Multivariate analysis of predictors for development of all SM showed that older age (p<0.001) and history of smoking (p< 0.001) were significant predictors for the development of a SM while treatment intervention was not found to be a significant variable. Among patients who developed a second cancer (n= 328) the 5-year mortality rates due to SM for RP, BRT and EBRT were 9.6%, 7.4% and 13.1%, respectively (p=0.3). CONCLUSIONS The incidence of SM after prostate cancer radiotherapy was not significantly different than surgery when adjusted for age of the patient and prior smoking history. The incidence of bladder and rectal cancers were low for both EBRT and BRT treated patients. Among patients who developed a SM the likelihood of mortality related to the SM was not different among the treatment cohorts. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e139 Peer Review Report Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tatiana Teslova New York, NY More articles by this author Xin Pei New York, NY More articles by this author Deborah Kuk New York, NY More articles by this author James Eastham New York, NY More articles by this author Juan Martin Magsanoc New York, NY More articles by this author Marisa Kollmeier New York, NY More articles by this author Brett Cox New York, NY More articles by this author Zhigang Zhang New York, NY More articles by this author Michael J. Zelefsky New York, NY More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...